Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

NCT00195286

Last updated date
Study Location
Antequera (Málaga), , , Spain
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Urinary Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients known, or thought to be hypersensitivity to beta-lactams


- Patients with an uncomplicated urinary tract infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Urinary InfectionsStudy Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286
  1. Antequera (Málaga),
  2. Avila,
  3. Barcelona,
  4. Berga (Barcelona),
  5. Caceres,
  6. Castellón,
  7. Ciudad Real,
  8. Cuenca,
  9. Cádiz,
  10. Ferrol,
  11. Granada,
  12. Jaen,
  13. Las Palmas,
  14. Lorca (Murcia),
  15. Lugo,
  16. Lérida,
  17. Madrid,
  18. Osuna (Sevilla),
  19. Palma Mallorca,
  20. Pamplona,
  21. Pontevedra,
  22. Terrasa,
  23. Torrelavega,
  24. Valencia,
  25. Valladolid,
  26. Vitoria,
  27. Zaragoza,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Official Title Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
Brief Summary The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients treated at internal medicine units
Condition Urinary Infections
Intervention Drug: piperacillin/tazobactam
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 24, 2009)
180
Original Enrollment
 (submitted: September 12, 2005)
300
Actual Study Completion Date July 2007
Actual Primary Completion Date July 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria:

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection
Sex/Gender
Sexes Eligible for Study:All
Ages 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT00195286
Other Study ID Numbers 101315
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date September 2009